Infectious diseases (London, England)最新文献

{"title":"60-day mortality and the role of SARS-CoV-2 in hospital admissions of immunocompromised patients during later Omicron period: a population-based study in Sweden.","authors":"Armin Spreco, Christer Andersson, Rune Sjödahl, Katarina Niward","doi":"10.1080/23744235.2025.2465828","DOIUrl":"10.1080/23744235.2025.2465828","url":null,"abstract":"<p><strong>Background: </strong>Real-world data on hospitalised SARS-CoV-2-positive patients are important for post-pandemic preventive measures.</p><p><strong>Objectives: </strong>This study aims to explore 60-day mortality of immunocompromised patients hospitalised in later Omicron period, accounting for the relevance of COVID-19 for hospital care.</p><p><strong>Methods: </strong>A retrospective population-based cohort study in Östergötland County, Sweden, included all adult patients with a positive SARS-CoV-2 PCR test within 3 weeks of hospital admission. Clinical data including functional level (combined assessment of frailty and performance status), and COVID-19's impact on hospital care were collected from medical records. An adjusted binary logistic regression model was applied for the main outcome of 60-day COVID-19-related mortality, with immunosuppression as the main exposure.</p><p><strong>Results: </strong>1128 hospitalised SARS-CoV-2-positive patients were included in the analysis whereof 12.9% were immunocompromised. Hospital admission due to COVID-19 was significantly more common among immunocompromised than non-immunocompromised (71.9% vs 49.5%), and 60-day COVID-19 mortality was 10.5% and 8.0% (<i>p</i> = 0.41), respectively. The median age of patients hospitalised due to COVID-19 was 78 years, with most having low/very low functional levels and ≥3 comorbidities. Adjusted for possible confounders, immunosuppression showed a significantly increased risk of 60-day COVID-19-related mortality (OR 2.41, 95% CI 1.06-5.47, <i>p</i> = 0.04).</p><p><strong>Conclusion: </strong>A majority of COVID-19-related hospitalisations during later Omicron period in a high immunity population, involved people over 70 years with low/very low functional levels and multiple comorbidities. Immunocompromised patients had a 2.5 times higher risk of 60-day COVID-19-related mortality. These findings underscore the need for targeted preventive measures in vulnerable elderly and immunocompromised populations to mitigate COVID-19-related hospitalisations and deaths.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"561-573"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of mortality in patients with Gram-Negative Bacilli (GNB) blood stream infections (BSI): multicentre data from India.","authors":"Nitin Bansal, Kalpesh Suresh Sukhwani, Veeren Ganta","doi":"10.1080/23744235.2025.2453581","DOIUrl":"10.1080/23744235.2025.2453581","url":null,"abstract":"<p><strong>Background: </strong>This study was done with objectives of determining the predictors of mortality in patients with Gram-Negative Bacilli (GNB) Blood stream Infection (BSI) along with estimating mortality attributable to carbapenem resistance (CR).</p><p><strong>Methods: </strong>In this prospective cohort study (January 2023-September 2024), done in 3 tertiary care centres in India, patients found to have mono-microbial GNB BSI were included. Primary outcome was crude mortality at day 30 of onset of BSI.</p><p><strong>Results: </strong>Out of 604 patients, mortality at day 30 happened in 140 (23.2%) patients. Intergroup analysis between patients alive (<i>n</i> = 464) and dead (<i>n</i> = 140) at day 30 revealed that lower age (<i>p</i> = 0.014), higher Sequential Organ Failure Assessment Score (SOFA) score (<i>p</i> < 0.001), higher Pitts Bacteraemia score (<i>p</i> < 0.001), acquisition of BSI in hospital (<i>p</i> = 0.003) and CR in <i>Enterobacterales (Escherichia coli</i> & <i>Klebsiella pneumoniae</i>[CRKP] and <i>Acinetobacter baumannii</i> (CRAB) and DTR (defined as non-susceptibility to carbapenems, β-lactam-β-lactamase inhibitor combinations, and fluoroquinolones) in <i>Pseudomonas aeroginosa</i> [DTR-PA] (CR <i>E. coli</i>, <i>p</i> = 0.034; CRKP, <i>p</i> = 0.012; CRAB, <i>p</i> < 0.001; DTR-PA, <i>p</i> < 0.001) was associated with higher mortality. On multivariate logistic regression analysis, higher SOFA score (<i>p</i> < 0.001) and BSI due to DTR-PA (<i>p</i> = .006) and CRAB (<i>p</i>= .017) were found to be independent predictors of mortality. Attributable mortality of CR in <i>E. coli</i> and <i>K. pneumoniae</i> and DTR in PA was 7.32, 8.43 and 52.4% respectively.</p><p><strong>Conclusion: </strong>We did not find CR as a major contributing factor for death among patients with BSI due to <i>Enterobacterales</i> in our study cohort.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"518-525"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carbapenemase production and in-hospital mortality associated with multidrug-resistant bacteria: a retrospective study conducted in Granada, Spain.","authors":"Pablo Redruello-Guerrero, Nicolás Francisco Fernández-Martínez, Cristina García-Marín, Luis Miguel Martín-delosReyes, Nicola Lorusso, Carlos Millán-Cachinero, María Del Carmen Valero-Ubierna, Mario Rivera-Izquierdo","doi":"10.1080/23744235.2025.2457535","DOIUrl":"10.1080/23744235.2025.2457535","url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant bacteria (MDR) represent a significant global health concern and vary in specific settings. Spain reported several annual deaths attributed to MDR bacteria, mainly carbapenemase-producing Enterobacterales.</p><p><strong>Objectives: </strong>We aimed to characterise the incidence and temporal trends of MDR bacterial infections or colonisations reported within the province of Granada (data from five hospitals), and to investigate factors linked to clinical vulnerability.</p><p><strong>Methods: </strong>We conducted an observational retrospective study (2014-2022) using the Andalusian Epidemiological Surveillance System. We employed descriptive, bivariate analyses and geographical mapping. Multivariable logistic regression models were adjusted to identify factors associated with (1) carbapenemase-production and (2) in-hospital mortality.</p><p><strong>Results: </strong>We included 1482 patients. The main microorganisms identified were <i>Klebsiella spp.</i>, <i>Escherichia spp</i>. and <i>Acinetobacter baumannii</i>. Carbapenemases were detected in 23% of cases, and were associated with higher in-hospital mortality rates (OR: 1.92; 95% confidence interval (95% CI): 1.31-2.81) and male sex (OR: 1.50; 95% CI: 1.01-2.23). The overall in-hospital mortality rate was estimated at 18.1%. Infections caused by <i>A. baumannii</i> (OR: 2.11; 95% CI: 1.41-3.13) or carbapenemase-producing <i>Klebsiella pneumoniae</i> (OR: 2.11; 95% CI: 1.28-3.45) were associated with increased mortality.</p><p><strong>Conclusions: </strong>These findings contribute to our understanding of the characteristics associated with carbapenemase-producing and early mortality resulting from MDR bacteria. This study offers insights into the factors associated with clinical vulnerability, which may improve future preventive measures.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"542-550"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 infection in inborn errors of immunity and their phenocopies: a systematic review and meta-analysis.","authors":"Saba Fekrvand, Kiarash Saleki, Hassan Abolhassani, Amir Almasi-Hashiani, Ali Hakimelahi, Nikan Zargarzadeh, Mir Saeed Yekaninejad, Nima Rezaei","doi":"10.1080/23744235.2025.2483339","DOIUrl":"10.1080/23744235.2025.2483339","url":null,"abstract":"<p><strong>Background: </strong>Inborn errors of immunity (IEI) are congenital disorders of the immune system. Due to impaired immune system, they are at a higher risk to develop a more severe COVID-19 course compared to general population.</p><p><strong>Objectives: </strong>Herein, we aimed to systematically review various aspects of IEI patients infected with SARS-CoV-2. Moreover, we performed a meta-analysis to determine the frequency of COVID-19 in patients with different IEI.</p><p><strong>Methods: </strong>Embase, Web of Science, PubMed, and Scopus were searched introducing terms related to IEI and COVID-19.</p><p><strong>Results: </strong>3646 IEI cases with a history of COVID-19 infection were enrolled. The majority of patients had critical infections (1013 cases, 27.8%). The highest frequency of critical and severe cases was observed in phenocopies of IEI (95.2%), defects in intrinsic and innate immunity (69.4%) and immune dysregulation (23.9%). 446 cases (12.2%) succumbed to the disease and the highest mortality was observed in IEI phenocopies (34.6%). COVID-19 frequency in immunodeficient patients was 11.9% (95% CI: 8.3 to 15.5%) with innate immunodeficiency having the highest COVID-19 frequency [34.1% (12.1 to 56.0%)]. COVID-19 case fatality rate among IEI patients was estimated as 5.4% (95% CI: 3.5-8.3%, <i>n</i> = 8 studies, I2 = 17.5%).</p><p><strong>Conclusion: </strong>IEI with underlying defects in specific branches of the immune system responding to RNA virus infection experience a higher frequency and mortality of COVID-19 infection. Increasing awareness about these entities and underlying genetic defects, adherence to prophylactic strategies and allocating more clinical attention to these patients could lead to a decrease in COVID-19 frequency and mortality in these patients.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"483-517"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.1080/23744235.2025.2513178","DOIUrl":"https://doi.org/10.1080/23744235.2025.2513178","url":null,"abstract":"","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A group with emerging potential in the clinical and public health realms: the genus <i>Providencia</i>.","authors":"J Michael Janda","doi":"10.1080/23744235.2025.2509007","DOIUrl":"https://doi.org/10.1080/23744235.2025.2509007","url":null,"abstract":"<p><strong>Background: </strong>The genus <i>Providencia</i> is increasingly being recognized as an important human pathogen. Previously a member of the family <i>Enterobacteriaceae</i> but now reclassified into the family <i>Morganellaceae</i> along with <i>Morganella</i> and <i>Proteus</i>, the phylogenetic depth of this clade has expanded from 3 species in its inception to 12 as of 2025. Recent clinical and epidemiologic data provide convincing evidence that <i>P. alcalifaciens</i> causes gastroenteritis and there is also increasing recognition of carbapenem-resistant strains of <i>P. stuartii</i> and <i>P. rettgeri</i> causing serious infections in hospital settings.</p><p><strong>Objective and methods: </strong>Since 2000, no comprehensive review of this genus has been published detailing taxonomic changes, ecological associations, emerging disease trends, pathogenicity and diagnostic modalities useful in detecting and typing providenciae. The objective of this article is to provide a current review and update of recent publications (PubMed, ScienceDirect, Google Scholar, Scopus^®) post-2000 and to summarize results and conclusions to date on this increasingly important genus.</p><p><strong>Results: </strong>Many reports have now been published describing human cases of enteritis and major outbreaks of gastroenteritis attributed to <i>P. alcalifaciens</i> and supported by multiple epidemiologic lines of evidence including typing methods (serology, molecular), in vivo immune responses, and case-controlled investigations. Similar disease syndromes have also been reported in dogs and pigs with one national canine outbreak of haemorrhagic diarrhoea reported from Norway in 2021. In addition, increasing drug resistance has been noted in both <i>P. stuartii</i> and <i>P. rettgeri</i> leading to the worldwide discovery of multi-, extensive-, and pan-resistant isolates causing disease which presents diagnostic issues in the laboratory and therapeutic challenges.</p><p><strong>Conclusion: </strong>The analysis reveals that providenciae are increasingly being implicated as important causes of intestinal and systemic disease. This is supported by a ten-fold increase in the number of <i>Providencia</i> studies listed in PubMed between 2000 and 2024. Methods need to be developed in the microbiology laboratory to recognize \"pathogenic\" strains of <i>P. alcalifaciens</i> that produce enteritis from commensal isolates. Emerging antimicrobial resistance needs to be detected early, monitored, and controlled to avoid further dissemination. New infection control prevention procedures need to be advanced and assessed for usefulness in medical care facilities.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-27"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the region.","authors":"Jonathan Haars, Frans Wallin, Karin Elfving, Anna-Karin Jonsson, Patrik Ellström, Paula Mölling, Johan Lindh, Hong Yin, Martin Sundqvist, René Kaden, Navaneethan Palanisamy, Johan Lennerstrand","doi":"10.1080/23744235.2025.2509011","DOIUrl":"https://doi.org/10.1080/23744235.2025.2509011","url":null,"abstract":"<p><strong>Background: </strong>Monoclonal antibodies (mAbs) are an important option against SARS-CoV-2, especially as pre-exposure prophylaxis (PrEP) for patients with immune system impairment. PrEP mAbs like sipavibart and pemivibart have been approved for limited use in several countries. Certain SARS-CoV-2 variants carry mutations in the spike (S) protein, conferring resistance to these mAbs.</p><p><strong>Objectives: </strong>We aimed to examine the relative abundance of different circulating SARS-CoV-2 variants/mutations in central Sweden between 2023 and 2024, and to predict the effectiveness of sipavibart and pemivibart.</p><p><strong>Methods: </strong>An amplicon-based Nanopore sequencing method was used for sequencing SARS-CoV-2 samples. Coronapp was used to identify mutations in these sequences. Using the published <i>in vitro</i> resistance data for sipavibart and pemivibart, the effectiveness of these mAbs was inferred.</p><p><strong>Results: </strong>We have observed that the relative abundance of the KP.3.1.1 variant and the Q493E mutation started to increase in the later part of 2024 in the region. Also, since April 2024, the relative abundance of the F456L mutation reached 100% during many weeks until the end of the study period. The KP.3.1.1 variant is significantly resistant to pemivibart. Further, the presence of the F456L mutation in the Omicron subvariants confers high fold resistance towards sipavibart.</p><p><strong>Conclusion: </strong>The use of sipavibart or pemivibart as PrEP for COVID-19 in the region may currently not be effective unless new SARS-CoV-2 variants appear not containing these resistance mutations. Further, new mAbs under development as PrEP for COVID-19 can be effectively used by routinely sequencing SARS-CoV-2 in patients to identify variants and resistance mutations.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of extended point-of-care lung ultrasound (EPLUS) for aetiological differentiation of lower respiratory tract infections: a prospective cohort study from India.","authors":"Lisa C Ruby, Stefan F Weber, Rajagopal Kadavigere, Raviraj Vedavyasa Acharya, Rahul Magazine, Barkur Ananthakrishna Shastry, Sowmya Joylin, Ayten Sultanli, Tom Heller, Kavitha Saravu, Sabine Bélard","doi":"10.1080/23744235.2025.2495708","DOIUrl":"https://doi.org/10.1080/23744235.2025.2495708","url":null,"abstract":"<p><strong>Background: </strong>Infectious respiratory diseases significantly cause morbidity and mortality worldwide, particularly in low- and middle-income countries (LMICs) with limited diagnostic resources. This study explored the utility of lung ultrasound (LUS) paired with extra-pulmonary point-of-care ultrasound (POCUS) for differentiating infectious aetiologies in lower respiratory tract infections (LRTI).</p><p><strong>Methods: </strong>This prospective cohort study was conducted at a tertiary care centre in India. We recruited consenting adults with suspected LRTI who underwent extended point-of-care lung ultrasound (EPLUS). The protocol included thoracic and abdominal views assessing for lung consolidations and B-lines, pleural effusion, pericardial effusion, focal splenic lesions, and abdominal lymphadenopathy and correlated these with patients' final diagnoses.</p><p><strong>Results: </strong>We included 322 participants in our analysis cohort, which had a notable prevalence of previously existing chronic lung conditions (21%) and an HIV-prevalence of 5%. Infectious lung disease was identified in 48% of patients, comprising 35% with non-TB LRTI and 13% with TB. Non-infectious lung disease was present in 21% of patients. LUS detected consolidations in 75% and >3 B-lines in 72% of participants. LUS findings were mostly non-specific and prevalent across both infectious and non-infectious conditions. Extra-pulmonary ultrasound findings, such as pericardial effusion and splenic lesions, findings common in disseminated tuberculosis, were rare.</p><p><strong>Conclusion: </strong>The study highlights the high sensitivity of LUS for detecting pulmonary changes but revealed low specificity to differentiate pulmonary conditions, especially in the presence of pre-existing comorbidities. Future research should explore the accuracy of combinations of clinical characteristics and ultrasound findings in algorithmic approaches, which may improve diagnostics in resource-limited settings.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of oral polio vaccine doses and severity of paralysis: an analysis of wild poliovirus type 1 cases in Pakistan.","authors":"Mohammed Soghaier, Zainul Abedin Khan, Nada Mutahar Taqi, Mukhtiar Hussain Bhayo, Faisal Rashid Lodhi, Abdu R Rahman","doi":"10.1080/23744235.2025.2503467","DOIUrl":"10.1080/23744235.2025.2503467","url":null,"abstract":"<p><strong>Background: </strong>Wild poliovirus type 1 (WPV1) transmission persists in Pakistan, with cases increasing from 6 in 2023 to 56 by November 2024, highlighting critical challenges in polio eradication efforts. The aim of this study is to assess the relationship between bivalent oral polio vaccine (bOPV) doses and the severity of paralysis in the confirmed WPV1 cases in Pakistan.</p><p><strong>Methods: </strong>We analysed all confirmed WPV1 cases reported in Pakistan from January 1, 2024, to November 15, 2024. Bivariate analyses were first conducted to explore initial associations. Firth, logistic regression models were then employed to evaluate the strength of these associations while adjusting for potential confounders.</p><p><strong>Results: </strong>Higher bOPV doses were significantly associated with a lower risk of severe paralysis in both univariate analysis (OR = 0.75, 95% CI: 0.60-0.93, <i>p</i> = 0.009) and after adjustment for age and sex (OR = 0.76, 95% CI: 0.59-0.97, <i>p</i> = 0.026). For residual paralysis after 60 days of onset, univariate analysis showed a significant association (OR = 0.77, 95% CI: 0.61-0.97, <i>p</i> = 0.026); however, this association was no longer statistically significant after adjustment (OR = 0.82, 95% CI: 0.64-1.05, <i>p</i> = 0.115).</p><p><strong>Conclusion: </strong>The study found a significant association between higher bOPV dose count and reduced paralysis severity in confirmed WPV1 cases. These findings suggest that bOPV may help to moderate the severity of paralysis, in addition to preventing WPV1 infection.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and outcomes of patients with infective native aortic aneurysm or vascular graft and endograft infection.","authors":"Lucas Lalevée, Malikov Sergueï, Elodie Jeanbert, Maïa Simon, Amandine Luc, Nicla Settembre, Sandrine Hénard, Emmanuel Novy, Philippe Guerci, Benjamin Lefèvre","doi":"10.1080/23744235.2025.2502826","DOIUrl":"https://doi.org/10.1080/23744235.2025.2502826","url":null,"abstract":"<p><strong>Background: </strong>Infections of the aorta and its branches can occur either in native tissue, known as infective native aortic aneurysms (INAAs), or following vascular surgery involving native or prosthetic grafts, referred to as vascular graft or endograft infections (VGEIs).</p><p><strong>Objectives: </strong>First, this study aimed to assess the all-cause on-year mortality of patients with INAAs and VGEIs. Second, this study described patients' characteristics and prognostic factors.</p><p><strong>Methods: </strong>This observational study included patients hospitalised for INAA or VGEI, between 2014 and 2022, at Nancy University Hospital (France). Data were retrospectively collected from patients' medical record (ClinicalTrials.gov ID NCT05660733).</p><p><strong>Results: </strong>Forty-seven patients were included in the INAAs group versus 40 in the VGEIs group. A history of immunosuppression or autoimmune disease were more frequent in INAAs patients. VGEIs patients had more chronic organ failure or cardiovascular pathology. The most commonly affected site was the infrarenal aorta, with thoracic involvement being more frequent in the INAAs group. <i>Staphylococcus aureus</i> was the most frequent identified pathogen (38.3% vs. 27.5%). There was no significant difference between groups in terms of all-cause 1-year mortality (40.4% in the INAAs group vs. 32.5% in the VGEIs group, log-rank test, <i>p</i> = .4803). The absence of surgery worsened the prognosis in the overall population (HR 2.8, 95% CI [1.2-6.3], <i>p</i> = .0125); this was also observed in the INAA group.</p><p><strong>Conclusions: </strong>Despite different comorbidities and clinical presentations between groups, there was no significant difference in 1-year mortality. Surgical management appeared to be associated with improved outcomes.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}